Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pediatrics. 2011 May;127 Suppl 1:S39-44. doi: 10.1542/peds.2010-1722G. Epub 2011 Apr 18.

Internet-based reporting to the vaccine adverse event reporting system: a more timely and complete way for providers to support vaccine safety.

Author information

  • 1Immunization Safety Office, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Mail Stop D-26, 1600 Clifton Rd, Atlanta, GA 30333, USA. phaber@cdc.gov

Abstract

BACKGROUND:

On March 22, 2002, Internet-based reports (IBRs) were added to the Vaccine Adverse Event Reporting System (VAERS) to allow rapid, expedited reporting of adverse events (AEs) in anticipation of wider use of counter-bioterrorism vaccines such as those against smallpox and anthrax.

OBJECTIVES:

To evaluate the impact of IBRs on the timeliness and completeness of vaccine AE reporting.

METHODS:

To evaluate timeliness and completeness, we compared the proportions of IBRs with non-Internet-based reports (NIBRs). Report interval was analyzed for timeliness and age at vaccination, birth date, and onset date for report completeness. To evaluate the impact of the smallpox vaccination program, we compared smallpox vaccine reports separately. Because influenza vaccine is the most widely used vaccine in adults each year, we compared influenza vaccine reports separately.

RESULTS:

During the study period, VAERS received 54 364 NIBRs (85.8%) and 9008 IBRs (14.2%). Sixteen percent (1455) of IBRs followed smallpox vaccination. Overall, for all vaccines and for smallpox vaccine alone, IBRs had a greater proportion of completeness and a shorter report interval. The proportion of most frequently reported AEs did not differ between IBRs and NIBRs. A higher proportion of adults (18-64 years old) who received influenza vaccine chose to complete an IBR (62% vs 48%).

CONCLUSIONS:

The improved timeliness and completeness of IBRs allow VAERS to more rapidly detect new or rare vaccine AEs. This important advantage is critical in times of increased public concern about vaccine safety. Clinical vaccine providers should be aware of VAERS and use IBRs whenever feasible to report vaccine AEs.

PMID:
21502243
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for HighWire
    Loading ...
    Write to the Help Desk